Description: Discover results of the ongoing SOA COVID-19 Group Life Mortality Survey. It will also compare Group Life mortality results to U.S. general population excess mortality trends, and explore some of the non-COVID drivers of excess mortality.

Description: Since its inception, the SOA Research Institute's Mortality and Longevity Strategic Research Program has introduced studies to provide insights into historical U.S. population mortality trends. Learn more about a recent focus that examines how causes of death are affecting trends. Come discover an overview of the research underway and discuss the latest findings including how causes of death are contributing to socioeconomic inequalities in U.S. mortality.

Description: Are you searching for an overview of the SOA Research Institute's Mortality & Longevity Strategic Research Program? Join us for an introduction into studies focusing on the historical U.S. population and insured mortality trends. Two research projects are observed in this webcast, one examining the impact of COVID-19 on mental illness and the impact of mental illness on U.S. Mortality & Longevity. The second study looks into the Group Life COVID-19 Mortality Survey and the high level view of U.S. group term life insurance mortality results during the pandemic. Come explore the research goals and the future for the Mortality & Longevity Strategic Program.

Description: The most recent U.S. population data released by the Centers for Disease Control and Prevention (CDC) and from the U.S. Census at year-end 2021 includes the first ten months of the COVID-19 pandemic in the U.S. While we know the pandemic has had significant impacts on both the U.S. population and insured population mortality, we also see increased mortality due to many other non-COVID causes of death. Where are the biggest changes and what does this non-COVID excess mortality mean over the next few years? Take part as an expert panel hosts an interactive discussion to examine data from general population as well as from both individual life and group life experience studies to explore how these changes might spur innovation in underwriting, assumption setting and pricing.

Description: It has been a little over a year since the release of the Society of Actuaries (SOA) Research Institute's Mortality Improvement Model, MIM-2021. Since then, waves of COVID-19 have continued to occur in the U.S. The uncertainty around the COVID-19 pandemic and the slowing of U.S. general population mortality improvement prior to the pandemic are just a few of the reasons that make developing MI projection scales difficult. Uncoverthe results from intercompany surveys on mortality improvement, including one that addresses COVID-19, discover insights from a mortality expert panel on COVID-19 and future mortality, and discuss enhancements to MIM-2021. By attending the session, you will: - Understand MIM-2021 and 2022 enhancements. - Understand SOA Research Institute activities around COVID-19 and impact on mortality improvement. - Apply research results and insights presented to daily work.

Description: Discuss changes in group life waiver of premium claim recovery and mortality experience since the 2005 table was released, the development of the 2023 table, and the new statutory valuation standard approved by the National Association of Insurance Commissioners (NAIC).

Description: The annuity market has been declining while the registered index-linked annuity (RILA) market has been expanding. Find outwhy the market is growing along with key features and considerations for the product from an actuarial perspective. By attending the session, you will: - Explain the increase in consumer demand and product opportunity. - Explain the key features and mechanics of a RILA. - Understand the pricing of RILA product. - Comprehend the key risks and ALM risks associated with RILA. - Explain high-level reserving mechanics of RILA under U.S. GAAP and U.S. statutory frameworks. - Understand the regulatory landscape impacting RILA products.

Description: COVID-19 had a major impact on mortality over the last several years both for the U.S. population and the insured population. Discuss excess deaths from both COVID-19 and other causes of death that have been observed during the pandemic. Review the trends seen in both the U.S population and the insured population’s deaths as well as a medical perspective as to what led to these changes in excess deaths that were not directly caused by COVID-19. Hear about predictions of what to expect for future mortality as a result of the COVID-19 pandemic. By attending the session, you will:•Identify drivers of excess deaths in both the U.S. population and insured population as a result of the COVID-19 pandemic.•Understand changes in the U.S. population’s health and behaviors that have contributed to these drivers.•Apply theses learnings when considering impacts to future mortality for the insured population.

Description: Discuss a comparison of the U.S. general and insured population mortality experience and how COVID-19 and non-COVID-19 excess deaths impacted the populations differently. Discover the population mortality experience in the UK with a focus on the recent emergence of excess deaths for non-COVID causes. The long-term implications on the insured population will also be explored. Wrap up with a discussion of different conditions of long COVID, including organ impairments.

Description: With mortality rates significantly higher in 2020 and 2021 due to the COVID-19 pandemic, actuaries that rely on historical experience cannot properly craft assumptions about the future due to the recent excess deaths. This webcast focuses on the practicality of using pandemic mortality experience, as well as how to overcome the practical challenges of that data implementation. Explore an overview of different approaches used by institutions in the U.S., Canada and UK and an observation of industry survey responses. There will also be a comparison to recent SOA expert opinion surveys and short term impacts on the future of U.S. mortality.